- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04567069
Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment
Phase I/II Study of DC Vaccine Targeting MG-7 Antigen to Treat Gastric Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All eligible patients will receive two cycles of treatment, every 21 days is a treatment cycle. The follow-up time will start from the next day after the end of the second cycle of treatment, and last for 48 ±1 weeks (the follow-up time is 4 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks). During the treatment and follow-up period, if disease progression or intolerable side effects develop, the patient can voluntarily request to be withdrawn from the study, or the investigators can determine that the patient be removed from the study.
DC and CTL are immune cells. PD-1 monoclonal antibody is an immune checkpoint inhibitor. According to the relevant experience of similar cells or drugs, some patients may have delayed or early pseudo-tumor progression after receiving immunotherapy, which needs to be judged by investigators.
In this study, the screening period is no more than 14 days. After the screening examination and evaluation, the eligible patients will enter the treatment period. The treatment and follow-up are carried out according to the procedure. The follow-up period: tumor imaging evaluation and related clinical indicator evaluation are carried out at the 4th week (± 1 week), the 12th week (± 1 week), the 24th week (± 1 week), the 36th week (± 1 week) and the 48th week (± 1 week) after the treatment. The patients should also complete the corresponding safety inspection and evaluation before leaving the group. During the follow-up period, the patients who do not have disease progression but do leave the group should continue to be evaluated according to the original frequency until the end of the follow-up period or the start of other anti-tumor treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Chengyun Zheng, Ph.D
- Phone Number: +86-531-85875502
- Email: zhengchengyun186@126.com
Study Contact Backup
- Name: Chenwei Li, Ph.D
- Phone Number: +86-18653168919
- Email: chenwei.li@sunstembio.cn
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250033
- Recruiting
- The 2nd Hospital of Shandong University
-
Contact:
- Chengyun Zheng, Ph.D.
- Phone Number: +86-531-85875502
- Email: zhengchengyun186@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically or cytologically confirmed gastric adenocarcinoma.
- Patients should be within age range of ≥18 and ≤80 years old, competent, have signed informed consent and have a life expectancy greater than 6 months.
- Failed in previous standard therapy ( surgery, chemotherapy, radiotherapy, and targeted therapy) or recurred from previous therapy, patients must be at least 1 month from their last therapy.
- Patients without indications of surgery, radiotherapy or chemotherapy.
- Patients who can't tolerate radiotherapy or chemotherapy.
- Patients who refuse radiotherapy or chemotherapy.
- Have measurable lesion by RECIST 1.1 criteria.
- Karnofsky Performance Status (KPS) ≥60.
- Patients must be willing to enroll the clinical study, and comply with the study and follow-up procedures.
Adequate organ and bone marrow functions:
- White Blood Count (WBC) ≥ 3,000/mm3 (3.0×109/L);
- Neutrophils≥ 1,000/mm3 (1.0×109/L);
- Platelets (PLT) ≥ 80,000/mm3 (80×109/L);
- Hemoglobin(Hb)≥ 9 g/dL (90g/L);
- Serum creatinine ≤ 1.5x the upper limit of normal (ULN) or creatinine clearance (CrCl)≥ 40 mL/min;
- Bilirubin≤ 1.5x ULN;
- Aspartate Aminotransferase (AST) ≤ 2.5x ULN or Alanine Aminotransferase (ALT) ≤ 2.5x ULN; patients with liver metastasis must be ≤5x ULN;
- International normalized ratio (INR) ≤ 1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN;
- Urine protein < 2 +; if urinary protein ≥ 2 +, the 24-hour urine protein quantification must be ≤ 1g.
Exclusion Criteria:
- Other diseases that may have influence on this study ( such as active infection, symptomatic myocardial infarction, angina pectoris, arrhythmia, etc.).
- Patients who received systemic anti-tumor therapy and local treatment (radiotherapy, ablation and embolization) for gastric cancer within 1 month.
- Patients who have active autoimmune diseases and need systemic immunosuppressive therapy.
- Life expectancy < 6 months.
- Patients with organ allografts.
- Women who are pregnant or nursing/breastfeeding
- Allergic to allogeneic protein.
- Human immunodeficiency virus (HIV) infection, untreated active hepatitis (hepatitis B, defined as HBV-DNA ≥ 500 IU / ml; hepatitis C, defined as HCV-RNA higher than the detection limit of the analytical method).
- For any other reasons, the patients are believed not suitable for participation in this study by investigators .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DC vaccine
Vaccine made from autologous dendritic cells loaded with MG-7 antigen.
|
Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection. Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time. Injection site: inguinal lymph nodes.
Other Names:
|
EXPERIMENTAL: DC vaccine + CTL (cytotoxic lymphocyte)
Cytotoxic lymphocytes are CD3+ T cells co-cultured with DCs.
|
Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection. Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time. Injection site: inguinal lymph nodes.
Other Names:
Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.
|
EXPERIMENTAL: DC vaccine + PD-1 monoclonal antibody (Sintilimab Injection)
Sintilimab injection is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells.
|
Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection. Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time. Injection site: inguinal lymph nodes.
Other Names:
The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) (PR+CR)
Time Frame: 6 months
|
The proportion of patients with complete response(CR) or partial response(PR) as measured by RECIST 1.1 criteria.
|
6 months
|
Disease Control Rate (DCR) (PR+CR+SD)
Time Frame: 6 months
|
The proportion of patients with complete response (CR), partial response (PR), or stable disease (SD).
|
6 months
|
Progression-free Survival (PFS)
Time Frame: 6 months
|
The length of time during and after the treatment, that a patient lives with the disease but it does not get worse.
|
6 months
|
Health-related quality of life (QoL): 36-Item Short Form (SF-36)
Time Frame: 6 months
|
Medical Outcomes Study 36-Item Short Form (SF-36)
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) (PR+CR)
Time Frame: 12 months
|
The proportion of patients with complete response(CR) or partial response(PR) as measured by RECIST 1.1 criteria.
|
12 months
|
Disease Control Rate (DCR) (PR+CR+SD)
Time Frame: 12 months
|
The proportion of patients with complete response (CR), partial response (PR), or stable disease (SD).
|
12 months
|
Progression-free Survival (PFS)
Time Frame: 12 months
|
The length of time during and after the treatment, that a patient lives with the disease but it does not get worse.
|
12 months
|
Health-related quality of life (QoL): 36-Item Short Form (SF-36)
Time Frame: 12 months
|
Medical Outcomes Study 36-Item Short Form (SF-36)
|
12 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DC-S-Ⅰ/Ⅱ
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on DC vaccine
-
Edward HirschowitzNational Cancer Institute (NCI)CompletedVaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung CancerLung CancerUnited States
-
Huashan HospitalRecruiting
-
Pawel KalinskiNational Cancer Institute (NCI)CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
Baylor Research InstituteTerminatedMalignant Melanoma Stage IVUnited States
-
Affiliated Hospital to Academy of Military Medical...RecruitingAcute Myeloid LeukemiaChina
-
Zwi BernemanKom Op Tegen Kanker; Research Foundation Flanders; Stichting tegen KankerActive, not recruitingAcute Myeloid LeukemiaBelgium
-
University of PennsylvaniaTerminated
-
Sichuan UniversityUnknown
-
Mackay Memorial HospitalUnknown
-
Shanghai Cell Therapy Group Co.,LtdRecruiting